Oncotarget published this trending research paper on January 31, 2022 in Volume 13, entitled, "Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study" by researchers from the Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT; Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, MN; Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Department of Hematology and Oncology, Baptist Health Medical Group, Lexington, KY; Department of Radiation Oncology, MetroHealth Medical Center, Cleveland, OH; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Department of Medicine, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Precision Oncology Program, Saint Luke’s Cancer Institute, Kansas City, MO; Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY; US Medical Oncology, Bristol Myers Squibb, Princeton, NJ; Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ; Global Medical Oncology, Bristol Myers Squibb, Princeton, NJ. DOI - https://doi.org/10.18632/oncotarget.28178 Correspondence to - Connor Willis - Connor.Willis@pharm.utah.edu Abstract: Background: Tumor mutational burden (TMB) is a potential biomarker to predict tumor response to immuno-oncology agents in patients with metastatic non-small cell lung cancer (NSCLC). Materials and Methods: A multi-site cohort study evaluated patients diagnosed with stage IV NSCLC between 2012 and 2019 who had received comprehensive genomic profiling (CGP) and any NSCLC-related treatment at 9 U.S. cancer centers. Baseline characteristics and clinical outcomes were compared between patients with TMB 10 showed a significant association towards longer overall survival (OS) (HR: 0.43, 95% CI: 0.21–0.88, p = 0.02) and progression-free survival (PFS) (HR: 0.43, 95% CI: 0.21–0.85, p = 0.02) in patients treated with first-line immunotherapy and tested by Foundation Medicine or Caris at treatment initiation. Conclusions: TMB levels greater than or equal to 10 mut/Mb, when tested by Foundation Medicine or Caris at treatment initiation, were significantly associated with improved OS and PFS among patients treated with first-line immunotherapy-containing regimens. Additional prospective research is warranted to validate this biomarker along with PD-L1 expression. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28178 Keywords - lung neoplasma, tumor biomarkers, immunotherapy About Oncotarget Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Analytical TechniquesCancer ResearchImmunologyMolecular Biology